文献速递胸部肿瘤头颈与中枢神经肿瘤

非黑色素瘤实体瘤免疫相关不良事件的预后价值前瞻性评估

Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
PubMed 文献 · Eur J Cancer · 2020-10-09

该前瞻性非干预ST-ICI试验纳入104例接受PD-1/PD-L1抑制剂单用或联合放疗的非黑色素瘤实体瘤患者,29例(28%)发生irAEs。发生irAEs者总生存(中位22.8 vs 9.0个月,p=0.001)和无进展生存(中位7.8 vs 3.2个月,p=0.002)均显著延长,联合放疗亚组结果一致。多因素分析仅肿瘤细胞PD-L1(p=0.049)和irAEs(p=0.001)为OS独立预测因素。

要点

  • irAEs发生率28%,放疗与否不影响irAEs发生率(p=0.668)。
  • 发生irAEs者OS和PFS显著更长,联合放疗亚组同样获益。
  • irAEs和肿瘤细胞PD-L1是OS独立预测因素。

核心结论

  • 发生irAEs是接受免疫治疗及免疫放疗实体瘤患者的有利预后因素。

研究设计与样本

  • 前瞻性非干预ST-ICI试验,纳入104例接受PD-1/PD-L1抑制剂单用或联合放疗的非黑色素瘤实体瘤患者。

主要发现

  • 29例(28%)发生irAEs,50例(48%)接受额外放疗。
  • 发生irAEs者中位OS为22.8个月 vs 无irAEs者9.0个月(p=0.001)。
  • 发生irAEs者中位PFS为7.8个月 vs 无irAEs者3.2个月(p=0.002)。
  • 联合放疗亚组中,发生irAEs者中位OS为22.8个月 vs 7.1个月(p=0.005),中位PFS为8.8个月 vs 3.0个月(p=0.005)。
  • 多因素分析仅肿瘤细胞PD-L1(p=0.049)和irAEs(p=0.001)为OS独立预测因素。

临床怎么用

  • 在接受PD-1/PD-L1抑制剂单用或联合放疗的非黑色素瘤实体瘤患者中,irAEs的出现可提示较好的预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prospective data about the prognostic value of immune-related adverse events (irAEs) in non-melanoma solid tumours are rare. The prognostic value of irAEs in patients treated with combined radiotherapy and immunotherapy is currently unknown. PATIENTS AND METHODS: The prospective non-interventional ST-ICI trial investigates treatment response of tumour patients to anti-programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors alone and in combination with radiotherapy and possible predictive markers. Patients undergoing immunotherapy or immunoradiotherapy were surveyed for irAEs. RESULTS: A total of 104 patients were included of whom 29 patients (28%) developed irAEs. Additional radiotherapy was performed in 50 patients (48%). Main tumour entities within the entire cohort were non-small cell lung cancer (NSCLC) (44%) and head and neck squamous cell carcinoma (42%). The rate of irAEs did not differ in patients with and without radiotherapy (p = 0.668). Patients who developed irAEs had longer overall survival (OS) (median: 22.8 months versus 9.0 months without irAEs, p = 0.001) and progression-free survival (PFS) (median: 7.8 months versus 3.2 months without irAEs, p = 0.002). In the subgroup with combined radiotherapy, patients with irAEs also had longer OS (median: 22.8 months versus 7.1 months without irAEs, p = 0.005) and PFS (median: 8.8 months versus 3.0 months without irAEs, p = 0.005). On multivariate analysis only PD-L1 on tumour cells (p = 0.049) and irAEs (p = 0.001) remained independent predictors of OS. CONCLUSION: The development of irAEs represents a favourable prognostic parameter in patients undergoing immunotherapy and immunoradiotherapy for solid tumours.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schweizer C, Schubert P, Rutzner S, et al. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. Eur J Cancer. 2020. PMID: 33045663. doi:10.1016/j.ejca.2020.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。